Gamma delta T cells from HIV⁺ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity

References

• Wren L, Kent SJ. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum Vaccin. 2011, 466–73.
   PubMedGoogle Scholar
• Beziat V, Duffy D, Quoc SN, Le Garff-Tavernier M, Decocq J, Combadiere B, . CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation. J Immunol. 2011;186:6753–61.
   PubMed Web of Science ®Google Scholar
• Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G, . FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood. 2004;104:1801–7.
   PubMed Web of Science ®Google Scholar
• Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, . Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood. 2009;113: 4875–84.
   PubMed Web of Science ®Google Scholar
• Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, . V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs rituximab and trastuzumab. Int J Cancer. 2008;122:2526–34.
   PubMedGoogle Scholar
• Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to V γ 9 Vδ2 T cell cytotoxicity. Cancer Immunol Immunother. 2007;56:1285–97.
   PubMed Web of Science ®Google Scholar
• Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, . Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS. 2009;23: 555–65.
   PubMed Web of Science ®Google Scholar
• Kottilil S, Jackson JO, Reitano KN, O'Shea MA, Roby G, Lloyd M, . Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr. 2007;46:151–9.
   PubMedGoogle Scholar
• Cummings JS, Cairo C, Armstrong C, Davis CE, Pauza CD. Impacts of HIV infection on V γ 2 V δ2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS. J Leukoc Biol. 2008;84:371–9.
   PubMedGoogle Scholar
• Hebbeler AM, Propp N, Cairo C, Li H, Cummings JS, Jacobson LP, . Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol. 2008;128:349–57.
   PubMedGoogle Scholar
• Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, . In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients. Cancer Immunol Immunother. 2009;58:31–8.
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, . Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:1283–8.
   PubMed Web of Science ®Google Scholar
• Ishihara S, Nieda M, Kitayama J, Osada T, Yabe T, Kikuchi A, . Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3–CD56+ NK cells in vitro. J Immunol. 2000;165:1659–64.
   PubMedGoogle Scholar
• Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR, . Isopentenyl pyrophosphate-activated CD56+{gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res. 2008;14:4232–40.
   PubMed Web of Science ®Google Scholar
• Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol. 2000;164:1148–52.
   PubMed Web of Science ®Google Scholar
• Klein JS, Webster A, Gnanapragasam PN, Galimidi RP, Bjorkman PJ. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. AIDS. 2010;24:1633–40.
   PubMedGoogle Scholar
• Wesch D, Marx S, Kabelitz D. Comparative analysis of alpha beta and gamma delta T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate. Eur J Immunol. 1997;27:952–6.
   PubMedGoogle Scholar
• Naoe M, Ogawa Y, Takeshita K, Morita J, Shichijo T, Fuji K, . Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res. 2010;18:493–501.
   PubMed Web of Science ®Google Scholar
• Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, . In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010;161:290–7.
   PubMedGoogle Scholar
• Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, . High phosphoantigen levels in bisphosphonate-treated human breast tumors promote V {gamma}9V{delta}2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71:4562–72.
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, . Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5:e1000433.
   PubMed Web of Science ®Google Scholar
• Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, . Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549–55.
   PubMed Web of Science ®Google Scholar
• Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. PLoS One. 2011;6:e18270.
   PubMed Web of Science ®Google Scholar
• Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, . Zoledronate-activated Vgamma9gammadelta T cell-based immunotherapy is feasible and restores the impairment of gammadelta T cells in patients with solid tumors. Cytotherapy. 2011;13:92–7.
   PubMed Web of Science ®Google Scholar